Our results, therefore, suggest that the accumulation of FRβ-expressing TAMs in the TME may limit endogenous tumor-specific T cell activity, as well as activity from adoptively transferred T cells, and rationalize the development of effective FRβ+ TAM-depleting approaches for cancer therapy. This evidence concerns the gene FOLR2 and cancer.